In 2023, the revenue from the PCR technologies market totalled USD 13,709.3 million, with a projected compound annual growth rate (CAGR) of 8.4% through the forecast period. This growth is anticipated to propel the market to reach USD 23,672.5 million by 2030.
This can be credited to the surge in communicable illness and genetic disorder occurrence and the surge in investments to advance diagnostic techs. Furthermore, the growing awareness of initial disease analysis and novelties in products is projected to boost the development of this industry.
In 2023, Reagents and consumables had the largest share, of more than 70%, and this category is projected to lead the product segment throughout the projection period. This is mainly because of the regular use of consumables and reagents for PCR testing. Basically, the growing occurrence of communicable diseases, particularly COVID-19, propels the industry in this category.
In 2023, real-time polymerase chain reaction held the largest share, and this category is projected to have a substantial CAGR, of 8%, during the projection period. This is mainly because it is one of the most extensively utilized methods throughout the globe in an extensive variety of applications, like species abundance quantification, cancer phenotyping, diagnostic test development, and gene expression analysis.
In 2023, the North American region accounted for the largest share, of 40%, and the region is projected to remain dominant in the future as well. This can be credited to the surge in the occurrence of communicable illness, improvement in the healthcare infrastructure, and the launch of advanced PCR instruments and consumables by key companies.
